On November 3, a technological documentation transfer agreement was signed with the Gamaleya Research Institute of Epidemiology and Microbiology. The technology transfer is expected to be completed by the end of the year.
In October, the Pharmasyntez-Nord factory passed a preliminary audit, within which the Gamaleya Research Institute technology experts confirmed the possibility of using the production complex for the vaccine manufacturing.
The factory has already prepared modern equipment for full-cycle manufacturing of the vaccine, including disposable systems for the substance production, as well as a set of equipment for the finished product manufacturing both in the solution and lyophilized form.
"We are confident and we are doing whatever is necessary to start manufacturing of the vaccine on an industrial scale in the 1st quarter of the next year", Mikhail Kvasnikov, General Director of Pharmasyntez-Nord JSC, said.